Proteomics technologies have revolutionized cell biology and biochemistry by providing powerful new tools to characterize complex proteomes, multiprotein complexes and posttranslational modifications. Although proteomics technologies could address important problems in clinical and translational cancer research, attempts to use proteomics approaches to discover cancer biomarkers in biofluids and tissues have been largely unsuccessful and have engendered considerable skepticism.
The National Cancer Institute has taken a leading role in facilitating the translation of proteomics from research to clinical application, through its Clinical Proteomic Technologies for Cancer (http://proteomics.cancer.gov). This program is designed to accelerate the transition of proteomics technologies from basic research tools to reliable and robust clinical research platforms. A major emphasis of the program is the optimization of technology platforms, standards development, and community reagents & resources development to address the challenges of clinical proteomics. This presentation will highlight the significant work of this initiative in building a more reliable and efficient protein biomarker development pipeline. It will do this in the context of the three phases of a biomarker discovery pipeline that we believe should be a standard roadmap to Discovery, Verification, and Validation. |
|
